83 results
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
14 Mar 24
Current report (foreign)
8:00am
, net
Tax receivable
Inventory
Unbilled revenue
Prepaid expenses
Restricted cash
Deposit on equipment
Investment at fair value through profit and loss …
Income taxes payable
Leases
Deferred acquisition payments
Leases
Deferred acquisition payments
Deferred income tax liability
Total liabilities
6-K
EX-10.1
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Current report (foreign)
5:29pm
Indebtedness.
(hh) Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material … Adverse Change, each of the Company and its Subsidiaries (i) has made or filed all U.S. and Canadian federal, state, provincial and local income tax
424B5
IPA
ImmunoPrecise Antibodies Ltd
23 Feb 24
Prospectus supplement for primary offering
5:26pm
as described herein may have tax consequences both in Canada and the United States. Such consequences for investors who are resident in, or citizens … of, Canada or the United States may not be described fully herein. See "Certain U.S. Federal Income Tax Considerations". The enforcement by investors
6-K/A
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
15 Feb 24
Current report (foreign) (amended)
3:12pm
receivable, net
Sales tax receivable
Income taxes receivable
Inventory
Unbilled revenue
Prepaid expenses
Restricted cash
Deposit on equipment … acquisition payments
Deferred income tax liability
Total liabilities
SHAREHOLDERS' EQUITY
Share capital
Contributed surplus
Accumulated other
6-K
EX-99.2
IPA
ImmunoPrecise Antibodies Ltd
14 Dec 23
Current report (foreign)
8:38am
tax receivable
Income taxes receivable
Inventory
Unbilled revenue
Prepaid expenses
Restricted cash
Deposit on equipment
Investment at fair … income tax liability
Total liabilities
SHAREHOLDERS' EQUITY
Share capital
Contributed surplus
Accumulated other comprehensive loss
Accumulated
424B5
se92q
7 Dec 23
Prospectus supplement for primary offering
4:53pm
6-K
EX-10.1
1vopz5
6 Dec 23
Current report (foreign)
5:19pm
6-K
vy19 3gw4oxtm3
6 Dec 23
Current report (foreign)
5:19pm
6-K
EX-8.1
7pejqp6j
6 Dec 23
Current report (foreign)
5:19pm
424B5
oyk5zpl
5 Dec 23
Prospectus supplement for primary offering
4:02pm
6-K
EX-99.2
vu4w7hhx0dgc pn
14 Sep 23
Current report (foreign)
8:02am
6-K
EX-10.1
mnnft6
15 Aug 23
Current report (foreign)
5:50pm
424B5
dao9ue
15 Aug 23
Prospectus supplement for primary offering
5:47pm
F-3
zasqocm
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
EX-4.4
buwifzyjbyj
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
EX-23.3
suk4brk
10 Jul 23
Shelf registration (foreign)
7:04pm
F-3
EX-4.3
79ljy1c
10 Jul 23
Shelf registration (foreign)
7:04pm
40-F
kilfmdmjopisf8c2mn
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.2
8myq ocljrwj50ru
10 Jul 23
Annual report (Canada)
4:32pm
40-F
EX-99.1
nu50dftdl3bpl zc
10 Jul 23
Annual report (Canada)
4:32pm